Impact of pharmacometric reviews on new drug approval and labeling decisions - a survey of 31 new drug applications submitted between 2005 and 2006

被引：87

作者：

Bhattaram, V. A. ^{[1
]}

Bonapace, C. ^{[1
]}

Chilukuri, D. M. ^{[1
]}

Duan, J. Z. ^{[1
]}

Garnett, C. ^{[1
]}

Gobburu, J. V. S. ^{[1
]}

Jang, S. H. ^{[1
]}

Kenna, L. ^{[1
]}

Lesko, L. J. ^{[1
]}

Madabushi, R. ^{[1
]}

Men, Y. ^{[1
]}

Powell, J. R. ^{[1
]}

Qiu, W. ^{[1
]}

Ramchandani, R. P. ^{[1
]}

Tornoe, C. W. ^{[1
]}

Wang, Y. ^{[1
]}

Zheng, J. J. ^{[1
]}

机构：

[1] Off Clin Pharmacol, Off Translat Sci, Ctr Drug Evaluat & Res, Food & Drug Adm, Silver Spring, MD USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷 / 02期

关键词：

D O I：

10.1038/sj.clpt.6100051

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Exploratory analyses of data pertaining to pharmacokinetic, pharmacodynamic, and disease progression are often referred to as the pharmacometrics (PM) analyses. The objective of the current report is to assess the role of PM, at the Food and Drug Administration (FDA), in drug approval and labeling decisions. We surveyed the impact of PM analyses on New Drug Applications (NDAs) reviewed over 15 months in 2005-2006. The survey focused on both the approval and labeling decisions through four perspectives: clinical pharmacology primary reviewer, their team leader, the clinical team member, and the PM reviewer. A total of 31 NDAs included a PM review component. Review of NDAs involved independent quantitative evaluation by FDA pharmacometricians. PM analyses were ranked as important in regulatory decision making in over 85% of the 31 NDAs. Case studies are presented to demonstrate the applications of PM analysis.

引用

页码：213 / 221

页数：9

共 7 条

[1] [Anonymous], 2006, DRUG APPROVAL PACKAG
[2] [Anonymous], 2005, DRUG APPROVAL PACKAG
[3] Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications
Bhattaram, VA
Booth, BP
Ramchandani, RP
Beasley, BN
Wang, YN
Tandon, V
Duan, JZ
Baweja, RK
Marroum, PJ
Uppoor, RS
Rahman, NA
Sahajwalla, CG
Powell, JR
Mehta, MU
Gobburu, JVS
[J]. AAPS JOURNAL, 2005, 7 (03) : E503 - E512
[4] The price of innovation: new estimates of drug development costs
DiMasi, JA
Hansen, RW
Grabowski, HG
[J]. JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) : 151 - 185
[5] Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process - Experience at Parke-Davis
Olson, SC
Bockbrader, H
Boyd, RA
Cook, J
Koup, JR
Lalonde, RL
Siedlik, PH
Powell, JR
[J]. CLINICAL PHARMACOKINETICS, 2000, 38 (05) : 449 - 459
[6] An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development - Experience within Hoffmann La Roche
Reigner, BG
Williams, PEO
Patel, JH
Steimer, JL
Peck, C
vanBrummelen, P
[J]. CLINICAL PHARMACOKINETICS, 1997, 33 (02) : 142 - 152
[7] 2005, DIV SPEC PATH TRANSP

← 1 →